Other Clinical Trial - Bristol Bladder Trial

Status Active, not recruiting

Clinical Trial Summary

26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given intravenously on day 1 of each 3 weekly cycle prior to radical cystectomy, to evaluate the overall response rate and to determine whether this approach warrants further research of a phase II/III study.Participation in 2 sub studies will also be offered to the participants. 1. Contrast Magnetic resonance imaging (MRI ) scans will be taken at baseline and after cycle 1 and cycle 3. 2. A pilot sub study involving the circulating tumour cell concentration from blood samples taken at baseline, prior to each cycle of chemotherapy and prior to surgery

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Infiltrating Bladder Urothelial Carcinoma

Clinical Trial Details

NCT number	NCT01616875
Study type	Interventional
Source	University Hospitals Bristol NHS Foundation Trust
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	May 2012
Completion date	January 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02944357` - Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery	N/A
Active, not recruiting	`NCT01495676` - A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer	N/A
Withdrawn	`NCT03419130` - Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer	Phase 2
Withdrawn	`NCT03238664` - Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors	N/A
Active, not recruiting	`NCT03549715` - NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma	Phase 1/Phase 2
Terminated	`NCT02767921` - sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer	Phase 1
Recruiting	`NCT03609216` - Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations	Phase 2
Withdrawn	`NCT02688348` - Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer	N/A